natgillin/translations-raw huggingface dataset:
Do not repeat Section 2 for routine use, if you do, you will run out of BYETTA before 30 days of use. • You are now ready for your first dose of BYETTA. • Go to Section 3, Step 3, for instructions on how to inject your first routine dose.
Pri vsakodnevni uporabi ne ponavljajte Poglavja 2, sicer vam bo zmanjkalo zdravila BYETTA še pred potekom 30 dni uporabe. • Sedaj ste pripravljeni za vaš prvi odmerek zdravila BYETTA. • Pojdite na Poglavje 3, Korak 3 za navodila glede injiciranja vašega prvega odmerka pri vsakodnevni uporabi.
If you cannot turn the dose knob, see Commonly Asked Questions, number 8, Section 4 of this user manual.
Če gumba za odmerjanje ne morete obračati v smeri urnega kazalca, glejte Pogosta vprašanja, številka 8, v Poglavju 4 tega Priročnika za uporabo.
Now that you have done the New Pen Setup, follow Section 3 for all of your injections.
VSAKODNEVNA UPORABA
STEP 1 Check the Pen
46 KORAK 1 Preverite injekcijski peresnik
46 • Wash hands prior to use. • Check pen label to make sure it is your 5 µg pen. • Pull off the blue pen cap.
• Pred uporabo si umijte roke. • Preverite oznako na injekcijskem peresniku, da zagotovite uporabo vašega 5 µg injekcijskega peresnika. • Snemite modri pokrovček injekcijskega peresnika.
• Check BYETTA in the cartridge. • The liquid should be clear, colourless, and free of particles.
• Preverite zdravilo BYETTA v vložku. • Tekočina mora biti bistra, brezbarvna in brez delcev.
A small air bubble will not harm you or affect your dose.
Majhen zračni mehurček v vložku je običajen.
Check that the is in the dose
Preverite, ali je v okencu za odmerjanje
If not, turn dose knob clockwise until it stops and the window.
urnega kazalca do konca, da je v okencu za odmerjanje
If you cannot turn the dose knob clockw ise to the
Če gumba za odmerjanje ne morete obračati v smeri urnega kazalca do vprašanja, številka 8, v Poglavju 4 tega Priročnika za uporabo.
• Grip pen firmly. • Insert needle into skin using hygienic injection technique recommended by your healthcare professional.
• Injekcijski peresnik čvrsto primite. • Vbodite iglo v kožo z uporabo higienske tehnike injiciranja, ki jo priporoča vaš zdravstveni delavec.
PUSH & HOLD • Use thumb to firmly push injection button in until it stops, then continue holding the injection button in while slowly counting to 5 in order to get a full dose. • Remove needle from skin.
PRITISNITE IN DRŽITE • S palcem čvrsto pritisnite gumb za injiciranje do konca, nato še naprej držite gumb za injiciranje pritisnjen, medtem ko počasi štejete do 5, da prejmete celotni odmerek. • Iz kože potegnite iglo.
Injection is complete when the The pen is now ready to reset.
Injiciranje je zaključeno, ko je v sredini okenca za odmerjanje Injekcijski peresnik je sedaj pripravljen za ponovno nastavitev.
If you see several drops of BYETTA leaking from the needle after the injection, the injection button was not pushed in all the way.
Če po injiciranju nekaj kapelj zdravila BYETTA izteka iz igle, gumba za injiciranje niste pritisnili do konca.
See Commonly Asked Questions, number 4, in Section 4 of this user manual.
Glejte Pogosta vprašanja, številka 4, v Poglavju 4 tega Priročnika za uporabo.
If you cannot turn the dose knob, or if your pen leaks, your full dose has not been delivered.
Če gumba za odmerjanje ne morete obračati v smeri urnega kazalca ali če iz vašega injekcijskega peresnika izteka, niste prejeli vašega celotnega odmerka.
See Commonly Asked Questions, numbers 4 and 8, in Section 4 of this user manual.
Glejte Pogosta vprašanja, številki 4 in 8, v Poglavju 4 tega Priročnika za uporabo.
• Remove the needle after each injection. • Carefully put the outer needle shield back over the needle.
• Iglo ostranite po vsakem injiciranju. • Previdno namestite zunanjo zaščito igle nazaj na iglo.
• Unscrew the needle. • Replace blue pen cap on pen before storage.
• Iglo odvijte. • Pred shranjevanjem na injekcijski peresnik ponovno namestite modri pokrovček peresnika.
• Throw away needles in a puncture-resistant container or as recommended by your healthcare professional.
• Igle zavrzite v embalažo, odporno proti vbodom, ali po navodilih vašega zdravstvenega delavca.
• Store your BYETTA pen properly.
49 • Ustrezno shranjujte vaš injekcijski peresnik BYETTA.
(See Storing Your BYETTA Pen in Section 1 of this user manual for more information.) • When it is time for your next routine dose, go to Section 3, Step 1, and repeat Steps 1 - 7.
(Za več informacij glejte Shranjevanje vašega injekcijskega peresnika BYETTA v Poglavju 1 tega Priročnika za uporabo.) • Ko je čas za vaš naslednji redni odmerek, pojdite na Poglavje 3, Korak 1 ter ponovite Korake 1
49 Section 4.
Poglavje 4.
Do I need to do the New Pen Setup before every dose? • No.
Ali moram pred vsakim odmerkom opraviti Pripravo novega injekcijskega peresnika? • Ne.
The New Pen Setup is done only once, just before each new pen is used for the first time. • The purpose of the setup is to make sure that your BYETTA pen is ready to use for the next 30 days. • If you repeat the New Pen Setup before each routine dose, you will not have enough BYETTA for 30 days.
Pripravo novega injekcijskega peresnika opravite samo enkrat, tik pred prvo uporabo vsakega novega injekcijskega peresnika. • Namen priprave je zagotovitev, da je vaš injekcijski peresnik BYETTA pripravljen za odmerjanje za naslednjih 30 dni. • Če pred vsakim rednim odmerjanjem ponovite pripravo novega injekcijskega peresnika, ne boste imeli dovolj zdravila BYETTA za 30 dni.
The small amount of BYETTA used in the New Pen Setup will not affect the 30-day supply of BYETTA.
Majhna količina zdravila BYETTA, ki se porabi pri pripravi novega injekcijskega peresnika, ne bo vplivala na zagotovitev količine zdravila BYETTA za 30 dni.
Why are there air bubbles in the cartridge? • A small air bubble is normal.
Zakaj so v vložku zračni mehurčki? • Majhen zračni mehurček je običajen.
It will not harm you or affect your dose. • If the pen is stored with a needle attached, air bubbles may form in the cartridge.
Ne bo vam škodoval ali vplival na vaš odmerek. • Zračni mehurčki v vložku lahko nastanejo, če injekcijski peresnik shranjujete s pritrjeno iglo.
What should I do if BYETTA does not come out of the needle tip after four tries during New Pen Setup? • Remove the needle by carefully putting the outer needle shield back over the needle.
Kaj naj storim, če zdravilo BYETTA ne priteče iz konice igle po štirih poskusih priprave novega injekcijskega peresnika? • Previdno namestite zunanjo zaščito igle nazaj na iglo in iglo odstranite.
Unscrew and dispose of properly. • Attach a new needle and repeat New Pen Setup, Steps B – E, in Section 2 of this user manual.
Odvijte jo ter ustrezno zavrzite. • Pritrdite novo iglo in ponovite pripravo novega injekcijskega peresnika, Korake B – E, v Poglavju 2 tega Priročnika za uporabo.
Once you see several drops or a stream of liquid coming out of the tip of the needle, the setup is complete.
Ko se na konici igle pojavi nekaja kapelj ali curek tekočine, je priprava končana.
It is normal for a single drop to remain on the tip of your needle after your injection is complete.
Zakaj po končanem injiciranju iz moje igle izteka zdravilo BYETTA Po končanem injiciranju je običajno, da na konici vaše igle ostane ena kaplja.
If you see more than one drop: • You may not have received your full dose.
Če vidite več kot eno kapljo: • Morda niste prejeli vašega celotnega odmerka.
Consult with your healthcare professional about how to handle a partial dose. • To prevent this, for your next dose, firmly push and hold the injection button in and slowly count to 5 (see Section 3, Step 4:
Posvetujte se s svojim zdravstvenim delavcem, kako ravnati v primeru delnega odmerka. • Da to preprečite, pri naslednjem odmerku čvrsto pritisnite in držite gumb za injiciranje ter počasi štejete do 5 (glejte Poglavje 3, Korak 4:
Inject the Dose).
Injicirajte odmerek).
These turn the dose knob in the next step.
Te puščice izvlečenje ali obračanje gumba za odmerjanje v naslednjem koraku.
This symbol ready to reset.
Ta simbol
arrows means the dose knob
kažejo smer za pomeni, da je gumb
show the direction to pull or is pushed in and the pen is
za odmerjanje pritisnjen ter, da je injekcijski peresnik pripravljen za ponovno nastavitev.
• You have firmly pushed the injection button in all the way until it stops and • You have slowly counted to 5 while you are still holding the injection button in and the needle is still in your skin and •
Injiciranje je končano, ko: • ste čvrsto pritisnili gumb za injiciranje vse do konca in • medtem ko še vedno držite pritisnjen gumb za injiciranje ter je igla še vedno v vaši koži, počasi štejete do 5 in •
is in the centre of the dose window.
je v sredini okenca za odmerjanje
Where should I inject BYETTA?
Kam naj injiciram zdravilo BYETTA?
BYETTA should be injected into your abdomen, thigh, or upper arm using the injection technique recommended by your healthcare professional.
Zdravilo BYETTA morate injicirate v trebuh, stegno ali nadlaket z uporabo tehnike injiciranja, ki jo priporoča vaš zdravstveni delavec.
Front Back
Spredaj
50 8.
Zadaj
If is in the dose window:
v okencu za odmerjanje
Pull the dose knob out until
Izvlecite gumb za odmerjanje,
appears.
da se pojavi
If is in the dose window and the dose knob will not turn: • The cartridge in your BYETTA pen may not have enough liquid to deliver a full dose.
• Vložek vašega injekcijskega peresnika BYETTA morda ne vsebuje zadosti tekočine za dajanje celotnega odmerka.
A small amount of BYETTA will always remain in the cartridge.
Majhna količina zdravila BYETTA bo vedno ostala v vložku.
If the cartridge contains a small amount or looks empty, obtain a new BYETTA pen.
Če vložek vsebuje malo tekočine ali izgleda prazen, si priskrbite nov injekcijski peresnik BYETTA.
If
Če sta v okencu za odmerjanje
and part of the
in del
are in the dose window and the dose knob cannot be pushed in:
in gumba za odmerjanje ne morete pritisniti:
Continue turning the dose knob clockwise until is in the centre of the dose window.
Obračajte gumb za odmerjanje v smeri urnega
and part of
in del
• The needle may be clogged, bent, or incorrectly attached. • Attach a new needle.
• Igla je morda zamašena, zvita ali nepravilno pritrjena. • Pritrdite novo iglo.
Make sure needle is on straight and screwed on all the way. • Firmly push the injection button in all the way.
Prepričajte se, da je igla privita naravnost in do konca. • Čvrsto pritisnite gumb za injiciranje do konca.
BYETTA should come from needle tip.
Zdravilo BYETTA bi moralo priteči iz konice igle.
If is in the dose window and the dose knob will not turn: • The injection button was not pushed in all the way and a complete dose was not delivered.
• Gumba za injiciranje niste pritisnili do konca in niste prejeli celotnega odmerka.
Consult with your healthcare professional about how to handle a partial dose. • Follow these steps to reset your pen for your next injection:
Posvetujte se s svojim zdravstvenim delavcem, kako ravnati v primeru delnega odmerka. • Sledite naslednjim korakom za ponovno nastavitev vašega injekcijskega peresnika za naslednje injiciranje:
- Firmly push the injection button in all the way until it stops.
- Čvrsto pritisnite gumb za injiciranje vse do konca.
Keep holding the injection button
Še naprej držite gumb za injiciranje
in and slowly count to 5.
pritisnjen in počasi štejte do 5.
Then turn the dose knob clockwise until window.
Nato obračajte gumb za odmerjanje v smeri urnega kazalca,
appears in the dose
dokler se v okencu za odmerjanje ne pojavi
- If you cannot turn the dose knob, the needle may be clogged.
- Če gumba za odmerjanje ne morete obračati, je morda zamašena igla.
Replace the needle and repeat
Zamenjajte iglo in
the step above. • For your next dose, be sure to firmly push and hold the injection button in and slowly count to 5 before removing needle from skin.
ponovite zgornji korak. • Pri naslednjem odmerjanju zagotovite, da boste gumb za injiciranje čvrsto pritisnili in držali ter počasi štejli do 5, preden boste iz kože izvlekli iglo.
51 PEN USER MANUAL
51 PRIROČNIK ZA UPORABO INJEKCIJSKEGA PERESNIKA
BYETTA 10 micrograms solution for injection, pre-filled pen (exenatide)
BYETTA 10 mikrogramov raztopina za injiciranje, napolnjen injekcijski peresnik (eksenatid)
This will help prevent leakage of BYETTA, keep out air bubbles, reduce needle clogs, and decrease the risk of infection. • Never push the injection button on the pen unless a needle is attached.
To bo preprečilo iztekanje zdravila BYETTA, nastanek zračnih mehurčkov, zmanjšalo zamaške v igli in zmanjšalo tveganje za infekcijo. • Nikoli ne pritisnite gumba za injiciranje injekcijskega peresnika, razen če je pritrjena igla.
52 How do I throw away my needles? • Throw away used needles in a puncture-resistant container or as recommended by your healthcare professional. • Do not throw away the pen with a needle attached.
52 Kako naj zavržem moje igle? • Uporabljene igle zavrzite v embalažo, odporno proti vbodom, ali po navodilih vašega zdravstvenega delavca. • Injekcijskega peresnika ne zavrzite s pritrjeno iglo.
53 BYETTA PEN PARTS
53 SESTAVNI DELI INJEKCIJSKEGA PERESNIKA BYETTA
DOSE WINDOW SYMBOLS ready to pull dose knob out ready to turn to dose position ready to inject 10 µg
SIMBOLI V OKENCU ZA ODMERJANJE Pripravljen za izvlečenje gumba za odmerjanja Pripravljen za obračanje za nastavitev odmerka Pripravljen za injiciranje 10 µg
• Wash hands prior to use. • Check pen label to make sure it is your 10 µg pen. • Pull off the blue pen cap.
• Pred uporabo si umijte roke. • Preverite oznako na injekcijskem peresniku, da zagotovite uporabo vašega 10 µg injekcijskega peresnika. • Snemite modri pokrovček injekcijskega peresnika.
54 • Pull off outer needle shield.
54 • Snemite zunanjo zaščito igle.
Turn dose knob clockwise until it stops at in the centre of the dose window.
Obračajte gumb za odmerjanje v smeri urnega kazalca, dokler se ne ustavi na Prepričajte se, da je podčrtana 5 na sredini okenca za odmerjanje.
55 • Point the needle of the pen up and away from you.
55 • Iglo injekcijskega peresnika usmerite navzgor in stran od sebe.
STEP 1 Check the Pen
56 KORAK 1 Preverite injekcijski peresnik
56 • Wash hands prior to use. • Check pen label to make sure it is your 10 µg pen. • Pull off the blue pen cap.
• Pred uporabo si umijte roke. • Preverite oznako na injekcijskem peresniku, da zagotovite uporabo vašega 10 µg injekcijskega peresnika. • Snemite modri pokrovček injekcijskega peresnika.
If not, turn dose knob clockw ise until it stops and the w indow.
urnega kazalca do konca, da je v okencu za odmerjanje
number 8, in Section 4 of this user manual.
, s glejte Pogosta
STEP 7 Store Pen for Next Dose
- 7.
59 Section 4.
Poglavje 4.
60 8.
Zadaj
61
61 62
Caelyx is concentrate to be made up into a solution for infusion (drip into a vein).
Zdravilo Caelyx je koncentrat, ki se pripravi v raztopino za infundiranje (dajanje tekočine v veno).
It contains the active substance doxorubicin hydrochloride (2 mg/ ml).
Vsebuje zdravilno učinkovino doksorubicinijev klorid (2 mg/ ml).
Caelyx is used to treat the following types of cancer: • metastatic breast cancer in patients at risk of heart problems. ‘ Metastatic’ means the cancer has spread to other parts of the body.
„ Metastatski “ pomeni, da se je rak razširil na druge dele telesa.
Caelyx is used on its own for this disease; • advanced ovarian cancer (cancer of the ovary) in women whose previous treatment including a platinum-based anticancer medicine has stopped working; • Kaposi’ s sarcoma (a cancer of the blood vessels) in patients with acquired immune deficiency syndrome (AIDS) who have very damaged immune systems and extensive sarcoma on the skin, the moist body surfaces or the internal organs.
Za to bolezen se zdravilo Caelyx uporablja samostojno. • Napredovalega raka jajčnikov pri bolnicah, pri katerih prejšnje zdravljenje, vključno s platinsko kemoterapijo, ni bilo več uspešno. • Kaposijevega sarkoma (rak žil) pri bolnikih s sindromom pridobljene imunske pomanjkljivosti (AIDS), ki imajo zelo prizadet imunski sistem in razširjen sarkom na koži, vlažnih telesnih površinah ali notranjih organih.
It is used when other treatments have stopped working or were not tolerated; • multiple myeloma (a cancer of the cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and are unsuitable for a bone marrow transplant.
Zdravilo se uporablja, ko druge oblike zdravljenja niso več uspešne ali jih bolnik ne prenaša dobro. • Multiplega mieloma (raka celic v kostnem mozgu) pri bolnikih z napredujočo boleznijo, ki so prejeli najmanj eno drugačno terapijo in niso primerni za presaditev kostnega mozga.
Caelyx should be given under the supervision of a doctor who is qualified in the use of cytotoxic (cell- killing) medicines.
Caelyx se sme uporabljati le pod nadzorom zdravnika, ki je usposobljen za dajanje citotoksičnih zdravil (zdravil, ki ubijajo celice).
The recommended starting dose of Caelyx for breast or ovarian cancer is 50 mg per square metre body surface area (calculated using the patient ’ s height and weight) every four weeks for as long as the disease does not get worse and the patient can tolerate the treatment.
Priporočeni začetni odmerek zdravila Caelyx za zdravljenje raka dojk in raka jajčnikov je 50 mg na kvadratni meter telesne površine (ki se izračuna iz telesne višine in mase bolnika) enkrat na vsake štiri tedne, dokler se bolezen ne poslabša in bolnica dobro prenaša zdravljenje.
For Kaposi’ s sarcoma, the dose is 20 mg/ m2 every two to three weeks for two to three months, and for multiple myeloma, it is 30 mg/ m2 on day four of each three-week cycle of bortezomib treatment, for as long as the patient continues to benefit from the treatment and can tolerate it.
Za Kaposijev sarkom je odmerek 20 mg/ m2 na vsaka dva do tri tedne v skupnem trajanju dva do tri mesece, za multipli mielom pa je odmerek 30 mg/ m2 na četrti dan vsakega tritedenskega cikla zdravljenja z bortezomibom tako dolgo, dokler bolniku zdravljenje koristi in ga dobro prenaša.
The active substance in Caelyx, doxorubicin hydrochloride, is a cytotoxic medicine that belongs to the group ‘ anthracyclines’.
Zdravilna učinkovina zdravila Caelyx je doksorubicinijev klorid, ki je citotoksično zdravilo iz skupine „ antraciklinov “.
It works by interfering with the DNA within cells, preventing them from making more copies of DNA and making proteins.
Deluje na DNA v celicah in preprečuje nastajanje več kopij DNA ter nastajanje beljakovin.
This means that cancer cells cannot divide and eventually die.
To pomeni, da se rakave celice ne morejo deliti in sčasoma odmrejo.
Caelyx accumulates in areas in the body where the blood vessels have an abnormal shape, such as within tumours, where its action is concentrated.
Zdravilo Caelyx se kopiči v telesnih delih, kjer imajo žile nenormalno obliko, npr. v tumorjih, kjer se njegovo delovanje skoncentrira.
Doxorubicin hydrochloride has been available since the 1960s.
Doksorubicinijev klorid je na voljo od šestdesetih let dalje.
In Caelyx, it is contained in ‘ pegylated liposomes’ (tiny fatty spheres that are coated with a chemical called polyethylene glycol).
V zdravilu Caelyx se doksorubicinijev klorid nahaja v „ pegiliranih liposomih “ (majhnih maščobnih kroglicah, ki so prevlečene s snovjo, ki ji pravimo polietilenglikol).
It also reduces its effects on non-cancer tissues and cells, so it is less likely to cause some side effects.
Ravno tako zmanjša učinke zdravila na nerakava tkiva in celice, zato z manjšo verjetnostjo povzroči določene neželene učinke.
Caelyx has been studied in a total of 2,512 patients in seven main studies.
Zdravilo Caelyx so preučili v sedmih glavnih študijah, v katere je bilo vključenih skupno 2512 bolnikov.
For metastatic breast cancer, Caelyx has been compared with standard doxorubicin in one main study involving 509 women.
Uporabo zdravila Caelyx za metastatski rak dojk so preučili s primerjavo z običajnim doksorubicinom v glavni študiji, v katero je bilo vključenih 509 žensk.
For advanced ovarian cancer, Caelyx has been compared with topotecan (another anticancer medicine) in one study involving 474 women who had received platinum-based chemotherapy in the past.
Uporabo zdravila Caelyx za napredovani rak jajčnikov so preučili s primerjavo s topotekanom (drugim zdravilom proti raku) v študiji, v katero je bilo vključenih 474 žensk, ki so se prej zdravile s platinsko kemoterapijo.
For AIDS-related Kaposi’ s sarcoma, the effectiveness of Caelyx was studied in two main studies involving 384 patients, including 77 who had received treatment before.
Učinkovitost zdravila Caelyx pri z AIDS- om povezanim Kaposijevem sarkomu so preučili v glavnih študijah, ki sta vključevali 384 bolnikov, vključujoč 77 bolnikov, ki so se že prej zdravili.
Further studies compared Caelyx with the combination of doxorubicin, bleomycin and vincristine (other anticancer medicines) in 258 patients and with the combination of bleomycin and vincristine in 241 patients.
V dodatnih študijah so primerjali zdravilo Caelyx s kombinacijo doksorubicina, bleomicina in vinkristina (drugih zdravil proti raku) pri 258 bolnikih ter s kombinacijo bleomicina in vinkristina pri 241 bolnikih.
For multiple myeloma, the effectiveness of the combination of Caelyx and bortezomib was compared with that of bortezomib alone in 646 patients.
Učinkovitost kombinacije zdravila Caelyx in bortezomiba pri multiplem mielomu so preučili s primerjavo s samostojno uporabo bortezomiba pri 646 bolnikih.
The main measure of effectiveness was time until the disease got worse or, for Kaposi’ s sarcoma, the number of patients who responded to treatment.
Glavno merilo učinkovitosti je bil čas do poslabšanja bolezni, pri Kaposijevem sarkomu pa število bolnikov, pri katerih so ugotovili odziv na zdravljenje.
What benefit has Caelyx shown during the studies?
Kakšne koristi je zdravilo Caelyx izkazalo med raziskavami?
In the treatment of breast cancer, Caelyx was as effective as standard doxorubicin: the time until the disease got worse was around 7.5 months in both groups.
Zdravilo Caelyx je bilo pri zdravljenju metastatskega raka dojk enako učinkovito kot običajni doksorubicin: čas do poslabšanja bolezni je bil v obeh skupinah bolnic približno 7, 5 mesecev.
However, patients receiving Caelyx were less likely to experience heart problems.
Vendar so ugotovili, da je bilo za bolnice, ki so prejemale Caelyx, manj verjeten pojav težav s srcem.
For ovarian cancer, Caelyx was as effective as topotecan in extending time until the disease got worse.
Pri podaljšanju časa do poslabšanja raka jajčnikov je bilo zdravilo Caelyx enako učinkovito kot topotekan.
For Kaposi’ s sarcoma, around 70% of the patients had a complete or partial response to treatment, with similar results in the study of patients who had been treated before.
Pri zdravljenju Kaposijevega sarkoma so pri 70% bolnikov ugotovili popoln ali delni odziv na zdravljenje ter podobne rezultate v študiji z bolniki, ki so se že prej zdravili.
The additional studies showed that Caelyx was also more effective than the comparator combinations.
V dodatnih študijah so dokazali, da je zdravilo Caelyx učinkovitejše od primerjanih kombinacij.
For multiple myeloma, adding Caelyx to bortezomib increased the time until the disease got worse from 6.5 to 9.3 months.
Z dodatkom zdravila Caelyx k bortezomibu za zdravljenje multiplega mieloma se je čas do poslabšanja bolezni podaljšal s 6, 5 na 9, 3 meseca.
The most common side effect seen in all types of cancer (in more than 1 patient in 10) is nausea (feeling sick).
Najpogostejši neželeni učinek, opažen pri vseh oblikah raka (pri več kot 1 bolniku od 10), je navzeja (slabost).